List of Lutathera drug patents
Lutathera is owned by Aaa Usa Inc.
Lutathera contains Lutetium Dotatate Lu-177.
Lutathera has a total of 2 drug patents out of which 0 drug patents have expired.
Lutathera was authorised for market use on 26 January, 2018.
Lutathera is available in solution;intravenous dosage forms.
Drug patent challenges can be filed against Lutathera from January, 2022.
The generics of Lutathera are possible to be released after 25 July, 2038.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10596276 | AAA USA INC | Stable, concentrated radionuclide complex solutions |
Jul, 2038
(15 years from now) | |
| US10596278 | AAA USA INC | Stable, concentrated radionuclide complex solutions |
Jul, 2038
(15 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jan 26, 2023 |
| Orphan Drug Exclusivity (ODE) | Jan 26, 2025 |
Drugs and Companies using LUTETIUM DOTATATE LU-177 ingredient
NCE-1 date: January, 2022
Market Authorisation Date: 26 January, 2018
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic